Travere Therapeutics (NASDAQ:TVTX) PT Raised to $20.00 at Bank of America
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target raised by Bank of America from $18.00 to $20.00 in a research report sent to investors on Wednesday, Benzinga reports. Bank of America currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on TVTX. Guggenheim raised […]
More Stories
Royal Bank of Canada Increases Guidewire Software (NYSE:GWRE) Price Target to $215.00
Guidewire Software (NYSE:GWRE – Get Free Report) had its target price lifted by equities research analysts at Royal Bank of...
B. Riley Financial, Inc. 5.25% Senior Notes due 2028 (RILYZ) To Go Ex-Dividend on October 15th
B. Riley Financial, Inc. 5.25% Senior Notes due 2028 (NASDAQ:RILYZ – Get Free Report) declared a quarterly dividend on Saturday,...
Abbott Laboratories (NYSE:ABT) Announces $0.55 Quarterly Dividend
Abbott Laboratories (NYSE:ABT – Get Free Report) declared a quarterly dividend on Thursday, September 19th, Wall Street Journal reports. Stockholders...
Carnegie Investment Counsel Has $23.90 Million Holdings in The TJX Companies, Inc. (NYSE:TJX)
Carnegie Investment Counsel decreased its holdings in shares of The TJX Companies, Inc. (NYSE:TJX – Free Report) by 1.1% in...
Bel Fuse Inc. (BELFA) to Issue Quarterly Dividend of $0.06 on November 1st
Bel Fuse Inc. (NASDAQ:BELFA – Get Free Report) declared a quarterly dividend on Wednesday, July 24th, Zacks reports. Shareholders of...
Carnegie Investment Counsel Purchases 12,430 Shares of Otis Worldwide Co. (NYSE:OTIS)
Carnegie Investment Counsel increased its holdings in Otis Worldwide Co. (NYSE:OTIS – Free Report) by 7.0% during the 3rd quarter,...